Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen

The New York Times - Business:

The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”

Author: Pam Belluck

This post first appeared in The New York Times - Business. Read the original article.